New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2014
10:00 EDTMU, FE, ETR, ED, ARMH, JMBA, UFS, MWV, PRU, JOY, GE, ENH, CB, SWIR, SON, WTM, MOG.A, IPCM, EXC, CNDO, AMCC, SNX, OI, SOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARM Holdings (ARMH) downgraded to Market Perform from Outperform at BMO Capital... Applied Micro (AMCC) downgraded to Market Perform from Outperform at BMO Capital... Chubb (CB) downgraded to Neutral from Buy at Janney Capital... Consolidated Edison (ED) downgraded to Neutral from Buy at Citigroup... Coronado (CNDO) downgraded to Perform from Outperform at Oppenheimer... Endurance Specialty (ENH) downgraded to Neutral from Buy at Janney Capital... Entergy (ETR) downgraded to Sell from Neutral at Citigroup... Exelon (EXC) downgraded to Sell from Neutral at Citigroup... FirstEnergy (FE) downgraded to Sell from Neutral at Citigroup... General Electric (GE) downgraded to Perform from Outperform at Oppenheimer... IPC The Hospitalist Co. (IPCM) downgraded to Neutral from Outperform at Credit Suisse... Joy Global (JOY) downgraded to Sell from Neutral at Goldman... Micron (MU) downgraded to Sector Perform from Outperform at RBC Capital... Moog (MOG.A) downgraded to Sector Perform from Outperform at RBC Capital... NRG Yield (NYLD) downgraded to Neutral from Buy at Citigroup... Prudential (PRU) downgraded to Neutral from Buy at Janney Capital... Sprint (S) downgraded to Sell from Hold at Stifel... White Mountains (WTM) downgraded to Neutral from Buy at Janney Capital... MeadWestvaco (MWV) downgraded to Neutral from Buy at BofA/Merrill... Owens-Illinois (OI) downgraded to Neutral from Buy at BofA/Merrill... Sonoco Products (SON) downgraded to Neutral from Buy at BofA/Merrill... Domtar (UFS) downgraded to Underperform from Buy at BofA/Merrill... SYNNEX (SNX) downgraded to Hold from Buy at Cross Research... Coronado (CNDO) downgraded at Oppenheimer... Jamba (JMBA) downgraded at Wedbush... Sierra Wireless (SWIR) downgraded to Equal Weight from Overweight at Stephens.
News For A;PRU;S;WTM;MWV;OI;SON;UFS;SNX;SWIR;JMBA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
07:47 EDTOIOwens-Illinois upgraded to Neutral from Underperform at BofA/Merrill
Subscribe for More Information
06:45 EDTOIOwens-Illinois upgraded to Neutral from Underperform at BofA/Merrill
Subscribe for More Information
May 15, 2015
17:15 EDTSPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
16:52 EDTJMBAEngaged Capital raises stake in Jamba to 10.2% from 9.1%
10:01 EDTPRUOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
05:51 EDTPRUPrudential initiated with a Neutral at Goldman
Target $89.
May 14, 2015
10:31 EDTST-Mobile says porting ratio vs. Sprint is approaching 3.0
In regards to LTE competition and sustainability, T-Mobile said it is in a leadership position where it really matters. Backs operating free cash flow and EBITDA guidance. Reports 11M MetroPCS subscribers. Comments taken from MoffettNathanson Media & Communications Summit.
06:06 EDTSDISH plans to enter wireless business, Yahoo reports
DISH (DISH) plans to enter the wireless business in an attempt to become the only provider to offer wireless voice, video and data services, Adam Samson of Yahoo Finance reports, citing an internal document. The document, marked confidential, obtained by Yahoo indicates Dish is looking to hire a chief marketing officer to help guide its move into the wireless space, Samson adds. The move comes after DISH acquired nearly half of the spectrum licenses offered in a U.S. government auction. The top U.S. wireless providers are Verizon (VZ), AT&T (T), T-Mobile (TMUS) and Sprint (S). Reference Link
May 13, 2015
16:23 EDTOIOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
15:27 EDTSStandard General acquires rights to RadioShack brand, data, WSJ says
Subscribe for More Information
10:07 EDTOIHigh option volume stocks
Subscribe for More Information
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
07:46 EDTOIOwens-Illinois sees Vitro deal adding 30c-40c to EPS in Year 1
Sees acquisition of Vitro's food & beverage glass container business leading to EPS accretion of about 50c in Year 3, as synergies are realized. Sees expected FCF accretion of >$100M by Year 3. Sees deal closing within 12 months, subject to Vitro shareholder approval and customary regulatory approvals. Sees $30M annual savings run rate expected by Year 3. Says "highly confident" in achieving synergies. Comments from slides discussing the deal to buy Vitro's food & beverage glass container business for $2.15B.
06:37 EDTOIOwens-Illinois to acquire Vitro's food and beverage business for $2.15B
Owens-Illinois announced that it has reached a definitive agreement with Vitro, S.A.B. de C.V. to acquire Vitro's food and beverage glass container business in an all-cash transaction valued at approximately $2.15B. The transaction, which has been approved by the boards of both companies, is subject to approval by Vitro's shareholders and customary regulatory approvals. The deal is expected to close within 12 months. The agreement includes Vitro's five plants in Mexico and one in Bolivia, which together employ 4,700 people. The current leadership of Vitro's food and beverage glass container business will remain in place following the transaction close. The acquired business is expected to generate estimated annual revenue of $945M and adjusted EBITDA of $278M. Further, O-I expects to realize approximately $30M in run-rate cost synergies by 2018 through a combination of procurement savings and operating efficiencies. The transaction is expected to be accretive to cash flow and earnings per share in the first year after closing.
May 12, 2015
12:02 EDTSVerizon, Sprint settle illegal billing investigations for $158M
Subscribe for More Information
08:31 EDTJMBAJamba increases share repurchase authorization to $40M from $25M
Subscribe for More Information
May 11, 2015
10:48 EDTPRUPrudential Real Estate Investors acquires retail, office portion of Mercato
Subscribe for More Information
08:11 EDTSNXMacquarie to hold a conference
Subscribe for More Information
06:19 EDTSRadioShack trademark, other IP up for auction, WSJ reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use